Article Figures & Data
Figures
- Fig 1.
Typical DNT findings.
A, Sagittal T1-weighted MR image shows a large lesion of low signal intensity involving the temporal lobe, without edema or mass effect and corresponding to a complex form of DNT. The lesion is divided by septations leading to an alveolar aspect.
B, The lesion is of high signal intensity on this T2-weighted MR image. The septations appear to be of low signal intensity.
C, Sagittal T1-weighted MR image shows a frontoparietal DNT with sharp boundaries and a rectangular pattern of distribution.
D, Coronal T2-weighted MR image illustrates the triangular pattern of distribution typical of DNT, with a tumor width that is maximal at the cortical level and decreases toward brain ventricles.
E, Low-magnification view showing the cortical location and the nodular architecture typical of DNT (hematoxylin phloxin-saffron, magnification ×10).
F, The glio-neuronal specific element is composed of oligodendrocyte-like cells surrounding areas of mucoid substance containing “floating neurons” (hematoxylin phloxin-saffron, magnification ×300).
- Fig 2.
DNT involving the occipital lobe and presenting hemorrhagic changes (case 7).
A, On CT scan, the lesion appears of low attenuation and shows a nodular enhancement after contrast injection.
B and C, On transverse (B) and sagittal (C) T1-weighted MR images, the DNT is of low signal intensity, displays septations, but shows three areas of hyperintensity after gadolinium injection, mimicking a glioma.
D, Transverse T2-weighted MR image shows the absence of edema and mass effect on median structure.
E, Marked nuclear atypias can be observed in the glial areas of DNT (hematoxylin phloxin-saffron, magnification ×200).
F, An oligodendroglioma-like area showing major hemorrhagic changes characterized by numerous hemosiderin-laden histiocytes (hematoxylin phloxin-saffron, magnification ×200).
Tables
Patient (no.) Age (y)/Sex Symptom Duration Seizure Type Extent of Resection Type of Resection Seizure Frequency at Last Medical Examination/Anticonvulsive Treatment Tumor Recurrence Follow-up (Months) 1 11/M 7 months Partial* Total Tumorectomy 0/No No 91 2 15/M 4 years Partial* Total Tumorectomy 0/No No 148 3 7/M 9 months Partial* Total Tumorectomy 0/No No 165 4 14/M 6 months Partial Total Tumorectomy 0/No No 29 5 9/F 8 months Partial Total Tumorectomy 0/Yes No 32 6 9/M 2 years Partial* Total Lobectomy 0/No No 63 7 12/F 9 months Partial Total Tumorectomy 0/No No 25 8 4/F 3 years Partial* Total Tumorectomy 0/No No 99 9 11/F 7 years Partial* Total Tumorectomy 0/No No 87 10 8/M 4 months Partial Total Tumorectomy Unchanged/yes No 36 11 3/M 5 months Partial* Total Tumorectomy 0/Yes No 36 12 18/F 14 years Partial* Total Tumorectomy 0/No No 167 13 6/M 2 years Partial* Total Tumorectomy 0 then recurrence/yes Yes 125 14 14/M 2 weeks Partial Total Tumorectomy 0/No No 117 * Drug-resistant seizures.
Patient (no.) Location CT MR Distribution Septations Skull Erosion Attenuation Contrast T1/T2 Contrast 1 Frontal Hypoattenuated NA ↓/↑ − Rectangular + + 2 Temporal NA NA ↓/↑ − Triangular + − 3 Temporal Hypoattenuated − ↓/↑ NA Triangular + − 4 Frontal Hypoattenuated − ↓/↑ − Rectangular + + 5 Temporal NA NA ↓/↑ Nodular Round + + 6 Temporal Hypoattenuated − ↓/↑ NA Triangular + + 7 Occipital Heterogeneous Nodular H/↑ Nodular Triangular + − 8 Frontoparietal NA NA ↓/↑ Nodular Rectangular + − 9 Temporal NA NA ↓/↑ − Triangular − − 10 Frontal Hypoattenuated − ↓/↑ NA Triangular + + 11 Temporal NA NA ↓/↑ − Triangular − − 12 Frontal NA NA ↓/↑ − Triangular + − 13 Frontal Hypoattenuated − ↓/↑ NA Round + + 14 Frontal Hypoattenuated − ↓/↑ − Round + − Note.—NA, not available; MRI, T1/T2 = T1-weighted image/T2-weighted image; ↓, hypointense lesion; ↑, hyperintense lesion; H, heterogeneous lesion; −, negative; +, positive.
Patient Cortical Dysplasia Glial Nodule Cell Type Calcifications Atypias Endothelial Proliferation Perivascular Inflammation Meningeal Involvement 1 C.U. + O − − − − + 2 M.I. NA O + P + ++ − − + 3 R.E. + O + − − − − 4 S.C. + O − − − − + 5 D.E. NA O + − − − − 6 B.E. + O + A − − − + − 7 B.O. − O + P − + − + + 8 L.A. + O − − − + + 9 Z.E. + O + + + − + 10 A.N. NA O − − − − − 11 C.H. + O − − − − − 12 A.Y. + None − − − − − 13 P.I. NA None − − − − − 14 C.E. NA None − − − − − Note.—O, oligodendrocytes; P, piloid cells; A, fibrillary astrocytes; −, negative; +, positive; NA, not available.
